Recombinant Newcastle disease virus expressing H9 HA protects chickens against heterologous avian influenza H9N2 virus challenge

详细信息    查看全文

• 作者：Abdou Nagy^a ; ^b ; Jinhwa Lee^a ; Ignacio Mena^c ; ^d ; Jamie Henningson^a ; Yuhao Li^a ; Jingjiao Ma^a ; Michael Duff^a ; Yonghai Li^a ; Yuekun Lang^a ; Jianmei Yang^a ; ^e ; Fatma Abdallah^b ; Juergen Richt^a ; Ahmed Ali^b ; Adolfo Garcí ; a-Sastre^c ; ^d ; ^f ; ^{adolfo.garcia-sastre@mssm.edu" class="auth_mail" title="E-mail the corresponding author} ; Wenjun Ma^a ; ^{wma@vet.k-state.edu" class="auth_mail" title="E-mail the corresponding author}
• 关键词：Influenza ; Recombinant NDV LaSota viruses ; H9N2 ; Cross-protection
• 刊名：Vaccine
• 出版年：2016
• 出版时间：17 May 2016
• 年：2016
• 卷：34
• 期：23
• 页码：2537-2545
• 全文大小：1787 K

文摘

In order to produce an efficient poultry H9 avian influenza vaccine that provides cross-protection against multiple H9 lineages, two Newcastle disease virus (NDV) LaSota vaccine strain recombinant viruses were generated using reverse genetics. The recombinant NDV-H9Con virus expresses a consensus-H9 hemagglutinin (HA) that is designed based on available H9N2 sequences from Chinese and Middle Eastern isolates. The recombinant NDV-H9Chi virus expresses a chimeric-H9 HA in which the H9 ectodomain of A/Guinea Fowl/Hong Kong/WF10/99 was fused with the cytoplasmic and transmembrane domain of the fusion protein (F) of NDV. Both recombinant viruses expressed the inserted HA stably and grew to high titers. An efficacy study in chickens showed that both recombinant viruses were able to provide protection against challenge with a heterologous H9N2 virus. In contrast to the NDV-H9Chi virus, the NDV-H9Con virus induced a higher hemagglutination inhibition titer against both NDV and H9 viruses in immunized birds, and efficiently inhibited virus shedding through the respiratory route. Moreover, sera collected from birds immunized with either NDV-H9Con or NDV-H9Chi were able to cross-neutralize two different lineages of H9N2 viruses, indicating that NDV-H9Con and NDV-H9Chi are promising vaccine candidates that could provide cross-protection among different H9N2 lineage viruses.